ANGO News and Press, AngioDynamics Inc. From 12/30/22

As painful as market volatility can be, investors can leverage this to their advantage. The Nasdaq Composite is loaded with growth-oriented stocks. And while this has been a good place to be for the last decade-plus, growth stocks have had no place to hide in 2022 with surging interest rates ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial re...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, Pres...

AngioDynamics, The PERT Consortium™ and Viz.ai partner on APEX Study to facilitate future enrollment to bring innovative treatment to patients with PE AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring heal...

As a growth investor, the key to building wealth is to buy decent companies in industries with compelling growth stories and hold for the long haul. Due to the launch of new and advanced medical devices to fill unmet needs, few industries will be able to match the growth of the medical ...

AngioDynamics, Inc. (ANGO) Q1 2023 Earnings Conference Call October 6, 2022, 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive Vice President and CFO Conference Call Participants Steven Lichtman - Oppenheimer &am...

The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: AngioDynamics, Inc. 2023 Q1 - Results - Earnings Call Presentation

Shares of small-cap medical technology company AngioDynamics (NASDAQ: ANGO) cratered in morning trading Thursday, falling 12.2% through 10 a.m. ET after missing on earnings this morning. Analysts had forecast that AngioDynamics would lose $0.02 per share ( pro forma ) on...

AngioDynamics press release ( NASDAQ: ANGO ): Q1 Non-GAAP EPS of -$0.06 misses by $0.04 . Revenue of $81.5M (+5.8% Y/Y) misses by $1.93M . Fiscal Year 2023 Financial Guidance: Management is reaffirming its previously issued fiscal year 2023 guidance. Man...

Fiscal Year 2023 First Quarter Highlights Net sales of $81.5 million increased 5.9% compared to the prior-year quarter Med Tech net sales of $22.8 million increased 29.6% Med Device net sales of $58.7 million decreased 1.1% Gross margin of 51....